| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE47826 | INNOCOLL PHARMS | Drug delivery device for providing local analgesia, local anesthesia or nerve blockage |
May, 2029
(5 years from now) | |
| US11746141 | INNOCOLL PHARMS | Modified collagen |
Jan, 2033
(8 years from now) | |
Xaracoll is owned by Innocoll Pharms.
Xaracoll contains Bupivacaine Hydrochloride.
Xaracoll has a total of 2 drug patents out of which 0 drug patents have expired.
Xaracoll was authorised for market use on 28 August, 2020.
Xaracoll is available in implant;implantation dosage forms.
Xaracoll can be used as a method for inducing a post-surgical analgesia sparing effect by implanting at the surgical site a collagen sponge containing bupivacaine hcl which provides local anesthesia for up to 24 hours following implantation.
The generics of Xaracoll are possible to be released after 09 January, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 28, 2023 |
Drugs and Companies using BUPIVACAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 August, 2020
Treatment: A method for inducing a post-surgical analgesia sparing effect by implanting at the surgical site a collagen sponge containing bupivacaine hcl which provides local anesthesia for up to 24 hours follow...
Dosage: IMPLANT;IMPLANTATION
XARACOLL family patents
